Antiseizure medication prescribing in people with Dravet syndrome: An analysis of real‐time administrative data
Epilepsia Open · 2025-02 · 10 (1) · 336-341
DOI: 10.1002/epi4.13105 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia Open, online erschienen am 05.12.2024. Verfasst von Kevin Y Xu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Epilepsies, Myoclonic, Anticonvulsants, Practice Patterns, Physicians', Drug Prescriptions. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDA NIH HHS, National Institute on Drug Abuse.
Abstract (Originalsprache)
Since 2018, three new antiseizure medications (ASMs) received FDA approval for Dravet syndrome (DS) in the U.S: cannabidiol, stiripentol, and fenfluramine. Yet, the uptake of these ASMs in routine clinical practice is unknown. We use new ICD‐10 codes for DS (implemented in 2020) to estimate ASM receipt in patients with DS. We analyzed the TriNetX Network, a real‐time electronic health record‐based dataset linked to prescription data encompassing all 50 states of the U.S. After identifying patients with health care encounters for DS in 2021 and 2022 (via ICD‐10 codes), we examined ASM prescribing in the year following a DS claim: 2022 and 2023, respectively. We retrieved 387 and 451 patients receiving claims for DS in 2021 and 2022, respectively. Clobazam, diazepam, valproate, midazolam, clonazepam, levetiracetam, and cannabidiol were the most common ASMs used (29%–44%). Stiripentol and fenfluramine prescribing was limited (7%–16%); these two ASMs, considered second‐line therapies in DS, were prescribed less often than ASMs considered third‐line or beyond. Cannabidiol, stiripentol, and fenfluramine prescribing rates remained nearly identical in the 2021 and 2022 cohorts. Our data suggests that stiripentol, fenfluramine, and, to an extent, cannabidiol may be underused in a large, diverse, primarily U.S.‐based population of patients with DS. Plain Language Summary In an analysis of routinely‐collected health care claims in the U.S., we found that the uptake of new antiseizure medications for Dravet Syndrome (i.e., stiripentol, fenfluramine, and cannabidiol) has been limited since 2022. Even though stiripentol and fenfluramine are considered second‐line treatments for Dravet syndrome, we found they were prescribed less frequently than medicines considered third‐line or beyond. These findings raise concern for underutilization of new antiseizure medications for Dravet syndrome in the United States.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.
- Institute for Public Health, Washington University School of Medicine, St. Louis, Missouri, USA.
- Department of Psychiatry and Behavioral Sciences, UCSF School of Medicine, San Francisco, California, USA.
- Department of Psychiatry and Behavioral Medicine, Carilion Clinic- Virginia Tech Carilion School of Medicine, Roanoke, Virginia, USA.
- Jane and John Justin Institute for Mind Health, Cook Children's Medical Center, Fort Worth, Texas, USA.
- Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
ORCID-Profile: Kevin Y Xu, Binx Yezhe Lin, M Scott Perry, Fábio A Nascimento
Förderung
- NIDA NIH HHS
- National Institute on Drug Abuse
Zitieren
APA
Xu, K. Y., Lin, B. Y., Perry, M. S., & Nascimento, F. A. (2025). Antiseizure medication prescribing in people with Dravet syndrome: An analysis of real‐time administrative data. Epilepsia Open, 10(1), 336-341. https://doi.org/10.1002/epi4.13105
Vancouver
Xu KY, Lin BY, Perry MS, Nascimento FA. Antiseizure medication prescribing in people with Dravet syndrome: An analysis of real‐time administrative data. Epilepsia Open. 2025;10(1):336-341. doi:10.1002/epi4.13105
BibTeX
@article{Xu2025,
author = {Xu, Kevin Y and Lin, Binx Yezhe and Perry, M Scott and Nascimento, Fábio A},
title = {Antiseizure medication prescribing in people with Dravet syndrome: An analysis of real‐time administrative data},
journal = {Epilepsia Open},
year = {2025},
volume = {10},
number = {1},
pages = {336--341},
doi = {10.1002/epi4.13105}
}
EUVIMED